Cost-effectiveness analysis of dupilumab among patients with uncontrolled severe asthma using LIBERTY ASTHMA QUEST Korean data

Table 3 Results of base-case analysis

	Add-on dupilumab to background therapy	Background therapy alone	Incremental
Number of exacerbations	36.341	31.636	4.705
Moderate exacerbations	18.421	11.725	6.697
Severe exacerbations	17.920	19.911	-1.992
Requiring office visit	5.088	5.654	-0.566
Requiring ED visit	1.438	1.598	-0.160
Requiring hospitalization	11.393	12.660	-1.266
Number of deaths	0.999	1.000	-0.001
Exacerbation-related deaths	0.871	0.968	-0.097
Non-asthma deaths	0.128	0.032	0.096
Drug costs^a (USD)	87,333	0	87,333
Disease management costs (USD)	5696	2716	2,980
Exacerbation-related costs (USD)	19,895	26,829	-6,934
Productivity loss costs^b (USD)	6317	16,851	-10,534
Due to morbidity	5378	15,173	-9,795
Due to premature death	939	1678	-739
Total costs (USD)^c	112,924	29,545	83,379
Total effectiveness (QALY gained)	8.03	3.93	4.10
ICER (USD/QALY)			20,325

All costs are expressed in 2023 USD using an exchange rate of 1 USD to 1310 KRW
ED Emergency department, ICER Incremental cost-effectiveness ratio, KRW Korean Won, QALY Quality-adjusted life-year, USD United States dollar
^aDrug costs included drug acquisition costs and drug administration costs
^bProductivity loss costs were only considered in the scenario analysis from a societal perspective
^cProductivity loss costs were not included

ISSN: 2191-1991